<i>RTTN</i>-mutated organoids exhibit decreased proliferation and increased cell death at early stages. حسب Justine Guguin (9088672)

MAP3K1, MAPK11, and PPP2R1A knockdown decreased ECM internalisation. حسب Montserrat Llanses Martinez (17797522)

Maximum IFN concentrations are decreased in severe patients. حسب Sonia T. Gazeau (21512764)

Lymphocytes decreased in mouse pneumonia model. حسب Qi Xu (134661)

Loss of Vps34 is associated with decreased eTreg survival but intact activation. حسب Erienne G. Norton (9612079)

الموضوعات:

Long-term anti-nucleocapsid response by baseline patient characteristics. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Madrasin decreases transcription of protein-coding genes. حسب Michael Tellier (8284752)

PDRN decreases the expression of cellular aging markers. حسب Jingjing Chen (293564)

Experimental validation revealed that ACADSB and ACADM decreased in patients with UC. حسب Hongliang Chen (538815)

K1 expression decreases in HA15 treated cells. حسب Guillermo Najarro (19964572)

Tetrandrine decreases Mtb antigen presentation. حسب Elham Karamooz (2584474)

Loss of <i>Rab23</i> decreases ciliation in MEFs and Tbr1 + intermediate progenitors. حسب Wan Ying Leong (22075947)

Cancer virtual patients with decreased initial neutrophil concentrations have higher viral load peaks. حسب Sonia T. Gazeau (21512764)

"…<p><b>A)</b> Viral loads in mild <b>a</b><b>-c)</b> and severe virtual patients <b>d</b><b>-f)</b>. <b>B)</b> Sensitivity analysis determined that decreasing <i>N</i>0 (the initial concentration of neutrophils) causes higher peak viral load and peak IL-6 and IFN concentrations.…"

Wnt signaling decreases the recruitment of RAB8a to basal bodies. حسب Cheng Yuan (160315)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Knock-down of DYRK1A decreases HBV RNAs levels in HBV-infected dHepaRG cells. حسب Florentin Pastor (19852287)

الموضوعات: "…chronically infected patients…"

Decreased <i>Notch3</i> asymmetry in <i>Nodal</i> mutants. حسب Tobias Holm Bønnelykke (20968460)